



ZAI Lab announces appointment of Dr. James Yan as Executive Vice President of Early Development and Drug Safety

Shanghai, China – October 23 2015 – Zai Lab Limited (Zai Lab), an innovative biotech company based in China, announced today the appointment of Dr. James Yan as its Executive Vice President and Head of Early Development and Drug Safety. Dr. Yan has over 15 years of experience in non-clinical drug development of both small molecules and biologics in the pharmaceutical industry.

"We are thrilled and fortunate to have Dr. Yan join the Zai team" said Samantha Du, Chief Executive Officer. "His diverse experience in drug non-clinical development will be invaluable to our company as we build a world class discovery and development team."

Prior to Zai Lab, Dr. Yan was the head of Covance Early Development (ED) Shanghai Site, where he successfully grew the team into 150+ employees and turned the business to profit with strong leadership foundations established. Dr. Yan started his career in the pharmaceutical industry with Pharmacia and was responsible for the development of a variety of new technologies for non-clinical drug safety assessments. He then joined Hospira, where he headed toxicology group and focused on toxicology programs supporting drug development and regulatory submissions. In 2009, Dr. Yan moved back to China as the head of Drug Safety Evaluation at Hutchison MediPharma. Over the course of his career, he was involved in IND and NDA filings for multiple drug candidates and gained substantial experience working with global regulatory agencies, including the US FDA, EMA, Australia TGA and China FDA (CFDA).

Dr. Yan received his PhD degree from Peking Union Medical University and post-doctoral training at the Ben-May Institute for Cancer Research, University of Chicago. He is a Diplomate of the American Board of Toxicology (DABT).

About Zai Lab

ZAI Lab is a leading biotech company based in China focused on discovering and developing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The

team has a strong track record of success – successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity. For more information, please visit www.zailaboratory.com